Valuation: Evotec AG

Market Cap 888M 1.01B 820M 765M 1.44B 96.07B 1.47B 9.83B 3.82B 47.37B 3.81B 3.73B 165B P/E 2026 *
-7.03x
P/E 2027 * -25.6x
Enterprise Value 903M 1.03B 833M 778M 1.46B 97.61B 1.49B 9.99B 3.88B 48.13B 3.87B 3.79B 168B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 1.17x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 70 2024-06-09
Director/Board Member 58 2019-06-18
Chairman 65 2026-06-10
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.01B
+1.15%+9.07%-3.67%+4.36% 46.62B
-2.77%+12.95%+407.40%+614.26% 40.95B
-0.03%+15.14%+22.70%-12.74% 32.26B
-1.73%+4.85%+18.15%+59.57% 32.24B
-3.29%+2.85%+13.80%+30.30% 25.53B
+1.15%+16.98% - - 16.38B
-0.96%+16.22%+70.46%+125.41% 15.27B
+0.56%+8.00%+12.65%+21.35% 13.61B
-1.74%+4.48%+99.22%+92.87% 13.34B
Average -0.77%+10.33%+80.09%+116.92% 26.24B
Weighted average by Cap. -0.89%+10.36%+94.41%+141.41%

Financials

2026 *2027 *
Net sales 738M 842M 681M 635M 1.2B 79.76B 1.22B 8.16B 3.17B 39.33B 3.16B 3.09B 137B 818M 934M 755M 704M 1.33B 88.44B 1.35B 9.05B 3.51B 43.61B 3.51B 3.43B 152B
Net income -113M -129M -105M -97.53M -184M -12.24B -187M -1.25B -486M -6.04B -486M -475M -21.03B -30.42M -34.74M -28.08M -26.2M -49.31M -3.29B -50.22M -337M -131M -1.62B -131M -128M -5.65B
Net Debt 14.3M 16.33M 13.2M 12.32M 23.18M 1.55B 23.61M 158M 61.44M 763M 61.36M 59.98M 2.66B 69.32M 79.18M 64M 59.71M 112M 7.5B 114M 767M 298M 3.7B 297M 291M 12.88B
Logo Evotec AG
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA